Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Reem Karmali"'
Autor:
Adam J. Olszewski, Brad S. Kahl, Christopher Del Prete, Thomas A Ollila, Victor M. Orellana-Noia, Craig A. Portell, Jun Lee, A. Mccook, Hanan Alharthy, Benjamin Echalier, Paolo F. Caimi, Natalie S Grover, Hayder Saeed, Daniel J. Landsburg, Ajay Major, Alexandra E Rojek, Jieqi Liu, Timothy Fu, Ranjana H. Advani, Yuxin Liu, Manali Kamdar, Stephen E. Spurgeon, Harsh Shah, Daniel R Reed, Emily C. Ayers, Jennie Y. Law, Jeremy M Sen, Jonathon B. Cohen, Jeffrey M. Switchenko, Reem Karmali, Scott F. Huntington, Timothy J Voorhees, Anson Snow, Julio C. Chavez, Frederick Lansigan, Jason T. Romancik, Mary-Kate Malecek, Brain T Hill, Christian M Barlow, Amy A. Ayers, Amulya Yellala, Mohammad Ahsan Sohail, Nadia Khan, Aleksandr Lazaryan, Deborah M. Stephens, Marcus P Watkins, Michael A. Spinner, Shazia Nakhoda, Kevin A. David, Avyakta Kallam, Odeth Barrett-Campbell, Vikram Raghunathan, Sonali M. Smith
Publikováno v:
Blood
Prophylaxis is commonly used to prevent central nervous sy stem (CNS) relapse in diffuse large B-cell lymphoma (DLBCL), with no clear standard of care. We retrospectively evaluated 1162 adult patients across 21 US academic centers with DLBCL or simil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6766d28bba0053ec72908d58e3a0859
https://europepmc.org/articles/PMC8777199/
https://europepmc.org/articles/PMC8777199/
Autor:
Craig S. Sauter, Farrukh T. Awan, Kwang Woo Ahn, Mohamed A. Kharfan-Dabaja, Manoj Khanal, Timothy S. Fenske, Victor A. Chow, Reem Karmali, Alireza Eghtedar, Allison M. Winter, Mehdi Hamadani, Carlos Litovich
Publikováno v:
Biol Blood Marrow Transplant
Disease relapse is the most common cause of therapy failure in patients with non-Hodgkin lymphoma (NHL) undergoing reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (allo-HCT). It is not known whether or not increasin
Autor:
Angel Mier Hicks, Julio C. Chavez, Amir Behdad, Emily C. Ayers, Jonathon B. Cohen, Daniel J. Landsburg, Catherine Diefenbach, Victor M. Orellana-Noia, Bita Fakhri, Michael C. Churnetski, Anshu Giri, Shaoying Li, Kami J. Maddocks, Rawan Faramand, Brian T. Hill, Christina Howlett, Jennifer E Amengual, Helen Ma, Craig A. Portell, Brian T. Hess, Yang Liu, Reem Karmali, Pallawi Torka, Adam J. Olszewski, Samuel Cytryn, Sarit Assouline, Madeira Curry, Radhakrishnan Ramchandren, Nishitha Reddy, Brad S. Kahl, Stefan K. Barta, Nina D. Wagner-Johnston, L. Jeffrey Medeiros, Dipenkumar Modi, David A. Bond, Ashwin Chandar, Lori A. Leslie, Dhruvika Mukhija, Kevin A. David, Sunita Nathan
Publikováno v:
Cancer. 126:293-303
BACKGROUND Salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation is the standard-of-care second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma after first-line R-CHO
Autor:
William Pearse, Jane N. Winter, Sonali M. Smith, Irene Helenowski, Leo I. Gordon, Amir Behdad, Jason B. Kaplan, Andreas K. Klein, Shuo Ma, Reem Karmali, Adam M. Petrich, Andrew M. Evens, Barbara Pro, Borko Jovanovic
Publikováno v:
Leukemialymphoma. 62(14)
Treatment strategies for post-transplant lymphoproliferative disorders (PTLD) consist of response-adapted risk-stratified methods using immunosuppression reduction, immunotherapy, and chemotherapy. We investigated the efficacy of Brentuximab vedotin
Autor:
Max J. Gordon, Timothy S. Fenske, Peter Martin, Natalie S Grover, Mary Malecek, Bhaskar Kolla, Brian T. Hill, Jeffrey M. Switchenko, Madelyn Burkart, Reem Karmali, Kami J. Maddocks, Jin Guo, David A. Bond, Stephanie Mathews, Narendranath Epperla, Michael C. Churnetski, Alexey V. Danilov, Talha Badar, Nilanjan Ghosh, Jonathon B. Cohen, Subir Goyal, Steven I. Park, Kristie A. Blum, Krithika Shanmugasundaram, James N. Gerson, Veronika Bachanova, Brad S. Kahl, Stefan K. Barta, Christopher R. Flowers, Yazeed Sawalha, Mehdi Hamadani
Publikováno v:
Am J Hematol
Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated in the rituximab era (2000-2015) at 12 US academic centers were assessed to identify determinants of survival across age groups. Objectiv
Autor:
Kwang Woo Ahn, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Farhad Khimani, Praveen Ramakrishnan Geethakumari, Sairah Ahmed, Yue Chen, Sachiko Seo, Nilanjan Ghosh, Narendranath Epperla, Mehdi Hamadani, Sanghee Hong, Amer Beitinjaneh, Pashna N. Munshi, Tim Prestidge, Leona Holmberg, Victor A. Chow, Michael Scordo, Yago Nieto, Natalie S Grover, Umar Farooq, Nada Hamad, Reem Karmali, Gerhard C. Hildebrandt, Andrew R. Rezvani, Jean A. Yared, Antonio Jimenez-Jimenez, Maxwell M. Krem, Bhagirathbhai Dholaria, Evgeny Klyuchnikov, Craig S. Sauter, David J. Inwards, Peter A. Riedell, Trent P Wang, Farrukh T. Awan, Alex F. Herrera, Andy I. Chen, Melhem Solh, Vaishalee P. Kenkre
Publikováno v:
JAMA Oncol
IMPORTANCE: Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for
Autor:
Pamela B. Allen, Ranjana H. Advani, Kaitlyn O'Shea, Hatice Savas, Robert Eisner, Leo I. Gordon, Joan S. Chmiel, Brett Alan Palmer, Reem Karmali, Jane N. Winter, Jeffrey Bearden, Barbara Pro, Robert Bayer, Andrew M. Evens, Gary Dillehay, Eric Mou
Publikováno v:
Blood
Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the complete metabolic response (CMR) rate and safety of pembrolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad788f725d552cec579bf7aeaeec958
https://europepmc.org/articles/PMC7955404/
https://europepmc.org/articles/PMC7955404/
Autor:
Kami J. Maddocks, Oscar Calzada, Brian T. Hill, Timothy F. Burns, Michael I. Wang, Julie M. Vose, Alexandra E. Kovach, Bhaskar Kolla, Andreas K. Klein, Bhargavi Pulluri, Alexandra M. Donovan, Frederick Lansigan, David J. Inwards, Jennifer K. Lue, Elizabeth Handorf, Martin Bast, Paolo Caimi, Jonathon B. Cohen, Jason B. Kaplan, Richard I. Fisher, Michael C. Churnetski, Timothy S. Fenske, Elvira Umyarova, Diego Villa, Parv Chapani, Veronika Bachanova, Yazeed Sawalha, David A. Bond, Julio C. Chavez, Martha Glenn, Shaoying Li, Marcus Messmer, Shalin Kothari, Alina S. Gerrie, Stefan K. Barta, L. Jeffrey Medeiros, Reem Karmali, Jennifer E Amengual, Amitkumar Mehta, Saurabh Rajguru, Nishitha Reddy, Andrew M. Evens, Swapna Narayana Rao Gari, Catherine Diefenbach, Nina D. Wagner-Johnston, James N. Gerson, Jennifer Kelly Anderson, Francisco J. Hernandez-Ilizaliturri, Bijal D. Shah, Daniel J. Landsburg
Publikováno v:
J Clin Oncol
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit r
Autor:
Madelyn Burkart, Nishitha Reddy, Suchitra Sundaram, Victor M. Orellana-Noia, Adam Zayac, Andrew M. Evens, Andreas K. Klein, Alessia Dalla Pria, Catherine Diefenbach, Ayushi Chauhan, Kristie A. Blum, Umar Farooq, Frank A. Post, Stephanie Berg, Michael C. Churnetski, Graham P. Collins, Deepa Jagadeesh, Agrima Mian, Alexey V. Danilov, David A. Bond, Yun Kyong Choi, Seema Naik, Vaishalee P. Kenkre, Scott E. Smith, Kirsten M Boughan, Craig A. Portell, Yong Lin, Seth M. Maliske, Izidore S. Lossos, Tatyana Feldman, Andrzej Stadnik, Adam J. Olszewski, Stephen D. Smith, Amandeep Godara, Gaurav Varma, Shireen Kassam, Peter Martin, Christopher D'Angelo, Mark Bower, Albert Ren, Reem Karmali, Narendranath Epperla, Bradley M. Haverkos, Silvia Montoto, Parameswaran Venugopal, Manali Kamdar, Nadia Khan, Kate Cwynarski, Maryam Sarraf Yazdy, Juan Pablo Alderuccio, Catherine Zhu, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Emma Rabinovich, Daniel Rector, Allandria Straker-Edwards, Catherine Wei, Paolo Caimi
Publikováno v:
Blood Adv
Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) patients with HIV-BL treated from 2008 to 20
Autor:
Elad Sharon, David S. Morgan, Neil Palmisiano, Catherine Diefenbach, Reem Karmali, Stephen M. Ansell, Jakub Svoboda, Brad S. Kahl, Stefan K. Barta, Michael J. Robertson, Kevin A. David, Richard F. Ambinder, Ranjana H. Advani, Jonathon B. Cohen, Fangxin Hong, Timothy S. Fenske, Howard Streicher
Publikováno v:
Lancet Haematol
Summary Background Recognising that the immune suppressive microenvironment promotes tumour growth in Hodgkin lymphoma, we hypothesised that activating immunity might augment the activity of targeted chemotherapy. We evaluated the safety and activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1337124261649e9dfc1e4bd74a0f4c96
https://europepmc.org/articles/PMC7737486/
https://europepmc.org/articles/PMC7737486/